Aevice Health and NUHS Launches Study To Detect Lung Sound Abnormalities Using Wearable Respiratory Monitor In Paediatric Patients

• Held at National University Hospital (NUH), the study will validate the use of a wearable respiratory monitor, the AeviceMD, to detect lung sound abnormalities, such as wheezing.

• The study builds on Aevice Health’s research collaboration with A*STAR Singapore to develop a predictive model for asthma attack among children.

Singapore, 27 October 2021 — Aevice Health, Singapore-based MedTech company dedicated to improving the lives of 545 million people with chronic respiratory disease, and the National University Health System (NUHS) today announced the launch of a study to use a novel respiratory monitor to detect lung sound abnormalities. The study, coordinated and facilitated by the NUHS Centre for Innovation in Healthcare (CIH), will investigate the use of Aevice Health’s proprietary wearable – the AeviceMD – in detecting wheezing in paediatric patients with breathing difficulties at the National University Hospital (NUH). Recruitment of study participants begun in September 2021 and the study is expected to conclude by the second quarter of 2022.

Wheezing is one of the key signs of respiratory diseases such as asthma, and asthma is one of the most prevalent chronic diseases of childhood. It is estimated to affect 14% of children worldwide. In Singapore, the disease affects about one in five children[1]. Many studies have shown that the chronic disease can be difficult to manage in children due to their inability to verbalise their symptoms or even realise that they are experiencing an exacerbation. This could lead to under-diagnosis, under-treatment and inadequate control of the disease[2].

The AeviceMD is a wearable respiratory monitor that detects and records chest sounds remotely and continuously. The chest sounds are then analysed and translated into heart rate and respiratory rate measurements, while abnormalities such as wheezing are flagged. Barely bigger than a US half-dollar coin and weighing less than 10 grams, the AeviceMD combines extremely comfortable and child-friendly form factor with highly accurate, longitudinal patient data to provide a new standard for remote patient monitoring.

“Aevice Health has developed a device that could allow the remote assessment of lung sounds in patients presenting with respiratory illnesses. The ability of the device to quantify wheeze and capture other lung sounds remotely will be studied in an upcoming clinical trial. It can potentially enhance remote patient monitoring and may be useful in situations such as the current COVID-19 pandemic where there is a need to minimise contact with patients. This ability to detect abnormal lung sounds may also find usefulness in homes to identify wheezing early in children and allow for prompt attention by the caregiver.” said Dr Michael Lim, Principal Investigator of the study and Senior Consultant, Division of Padiatric Pulmonary Medicine and Sleep, Department of Paediatrics, Khoo Teck Puat – National University Children’s Medical Institute, NUH.

“Currently, there is no widely adopted solution in market that is able to objectively identify and analyze lung sound abnormalities continuously and remotely in patients. This study will further validate AeviceMD’s value to providers and patients by empowering the detection of lung sound abnormalities objectively, continuously, and remotely to further bridge the gap between providers and clinicians,” said Adrian Ang, Chief Executive Officer of Aevice Health.

Concurrently, the company is working towards conducting research and development on a predictive model for asthma attack among children using continuous measures from a wearable device. The study, a collaboration with partners in Singapore, will potentially unlock insights into how clinicians and researchers can use continuous measurement of physiological signals to detect early signs of asthma attacks.

“This study, alongside our research collaboration on the predictive model, will have a significant and profound impact on the way we understand chronic respiratory disease. The use of AeviceMD as a novel remote respiratory monitor can unlock insights beyond the hospital for providers to better understand factors leading up to an exacerbation to allow for more tailored and patient-centered outcomes. We are excited by how the use of the AeviceMD can enhance the way chronic respiratory disease is being treated and understood,” Ang added.

Earlier in July, Aevice Health announced its Pre-Series A funding from investors Toho Holdings Co Ltd, Pureland Group Venture, Silicon Solutions Partners, AIP Ventures, and SEEDS Capital, the investment arm of government agency Enterprise Singapore. Part of the funding will be used to power the study as part of the company’s and its investors’ commitment to improve the management and understanding of chronic respiratory disease.

[1] Asthma (Common Childhood Illnesses), Health Hub Singapore

[2] Challenges in the treatment of asthma in children and adolescents

About Aevice Health

Aevice Health Pte Ltd is a Singapore-based MedTech spin-off from Nanyang Technological University at the forefront of addressing chronic respiratory disease, one of the generation’s biggest healthcare challenges.

The company’s non-invasive wearable devices enable the early detection of cardiopulmonary abnormalities remotely and in real-time, so that patients can receive fast and targeted care from the ease of their homes. Clinicians can also gain insights into their patients’ health and track their responses to treatment plans easily from the Aevice analytical platform.

In Aevice Health, our mission is to drive medical innovations that transform healthcare, improve outcomes and empower lives.

More information about the company can be found at www.aevice.com.

About NUHS CIH

The NUHS Centre for Innovation in Healthcare (CIH) is one of six NUHS Centres of Excellence (CoEs) location at Alexandra Hospital.  It aims to develop and implement new models of care, incorporating smart technologies as well as innovations in research and training to meet present and future national healthcare needs. CIH actively facilitates inter-disciplinary research, innovation and enterprise across science, engineering and other disciplines and provides a one-stop ecosystem to testbed solutions including new devices, technologies and work processes, at scale.

About National University Hospital

The National University Hospital is a tertiary hospital and major referral centre with over 50 medical, surgical and dental specialties, offering a comprehensive suite of specialist care for adults, women and children. It is the only public hospital in Singapore to offer a paediatric kidney and liver transplant programme, in addition to kidney, liver and pancreas transplantation for adults.

The hospital was opened on 24 June 1985 as Singapore’s first restructured hospital. Each year, the Hospital attends to more than one million patients.

As an academic health institution, patient safety and good clinical outcomes are the focus of the Hospital. It plays a key role in the training of doctors, nurses, allied health and other healthcare professionals. Translational research is pivotal in the Hospital’s three-pronged focus, and paves the way for new cures and treatment.

A member of the National University Health System, it is the principal teaching hospital of the NUS Yong Loo Lin School of Medicine and the NUS Faculty of Dentistry.

For media enquiries, please contact:

Janelle Low
Aevice Health Pte Ltd
Email: janellelow@aevice.com

Yvonne Lee
National University Health System
Email: Yvonne_Lee@nuhs.edu.sg

Justine LAI
Assistant Manager, Group Communications Office
National University Health System
Mobile: 97380669
Email: justine_lai@nuhs.edu.sg

Aevice Health is selected for Sunway iLabs Pre-Accelerator Programme

Malaysia, 5 July, 2021 – Aevice Health is pleased to announce that we are part of the Top 23 startups selected for Sunway iLabs Pre-Accelerator Programme.

The Sunway iLabs Accelerator Programme is designed to bring selected startups to the next level. Selected startups will have access to markets, mentors, and money. Selected startups will go through a 1-month pre-accelerator, of which only the Top 5 will qualify for the investment and pilot projects with Sunway through the next 3-months accelerator.

The Pre-Accelerator Programme will start on 5 July 2021.

Read more about the programme here.

Jiva.AI and Aevice Health Collaborate to Pioneer Breakthrough Medical AI for Asthma Adverse Event Prediction Based on Aevice Health’s FDA-cleared Remote Patient Monitor

 Singapore, London, 2 February 2024 – Jiva.ai, a leading no-code AI platform, and Aevice Health, a prominent provider of remote respiratory monitoring solutions for the healthcare continuum, today announced their collaboration on a jointly funded co-innovation programme by Innovate UK and Enterprise Singapore aimed at creating a state-of-the-art medical AI to predict asthma exacerbations.

The collaboration represents a synergistic blend of Jiva.ai’s cutting-edge AI capabilities and Aevice Health’s expertise in developing a proprietary remote patient monitoring platform that empowers individuals to proactively manage their respiratory health. The project will see the development of an AI capable of asthma exacerbation prediction, utilizing Aevice Health’s FDA-cleared AeviceMD, to provide asthma patients with a groundbreaking tool to take charge of their conditions.

Asthma poses a significant global healthcare burden, with billions spent on reactive management only in the advanced stages. Advancements in remote technology has generated extensive data that holds promise for early asthma prediction and management. Similarly, development in AI technology now offers a possibility to creating diagnostic and prognostic tools that could reduce patient suffering, save lives, and cut costs to healthcare systems.

Implementing a “multimodal AI”, the ability to read multiple different types of data to make predictions, within a clinical setting can be complex. Multimodal AI ideally involves adding new predictors to existing AI models, which is desirable but technologically and logistically difficult in healthcare. With the FDA-cleared AeviceMD, biomarkers of interest for asthma exacerbations can be collected unobtrusively and continuously within and outside of clinical settings. The diverse data collected can then be integrated into the multimodal AI to create an early warning system for asthmatic patients to get the care they need before their asthma escalates.

“Combining Jiva.ai’s no-code AI platform with Aevice Health’s advanced remote patient monitoring platform is a significant leap forward in the realm of healthcare innovation,” said Dr Manish Patel, CEO at Jiva.ai. “We are excited about the potential impact of this collaboration, as it underscores our commitment to leveraging technology to enhance patient outcomes and improve overall healthcare delivery.”

Aevice Health’s CTO, Dr Rex Tan, echoed this sentiment, stating, “Asthma is a global health concern, and our collaboration with Jiva.ai through the Enterprise Singapore and Innovate UK jointly funded co-innovation project aligns with our mission to empower individuals to actively manage their respiratory health.”

This project will leverage the strengths of both companies to develop an intelligent and user-friendly care regime that integrates seamlessly into patients’ lives. The collaboration is set to redefine the landscape of respiratory health management, demonstrating the potential of AI-driven solutions in addressing complex healthcare challenges.

The UK-Singapore Collaborative R&D grant call is a programme jointly launched by Innovate UK, part of the UK Research and Innovation, and Enterprise Singapore. The grant’s objective is to fund business-led collaborative research and development (CR&D) projects between the UK and Singapore, focused on industrial research in particular sectors including health and life sciences.

As the project unfolds, Jiva.ai and Aevice Health anticipate not only advancing the frontiers of medical technology but also making substantial contributions to the broader discourse on harnessing AI for proactive healthcare measures.

About Aevice Health

Aevice Health is a digital health company dedicated to improving asthma and COPD care through its proprietary, non-invasive remote patient monitoring platform and wearable stethoscope, the AeviceMD. Its cutting-edge technology allows for continuous monitoring and real-time disease deterioration tracking, enabling patients to receive personalized care from the comfort of their homes. With actionable insights and effortless treatment response monitoring, healthcare professionals can make timely adjustments for optimized patient outcomes. Aevice Health is on a mission to improve healthcare accessibility, empower patients, and reduce healthcare costs.

More information about the company can be found at www.aevice.com.

About Jiva.AI

Jiva.ai is a leading no-code AI platform that empowers organisations to harness the power of artificial intelligence without the need for extensive coding expertise. With a focus on healthcare, Jiva.ai is committed to driving innovation in the industry and improving patient outcomes through accessible and user-friendly AI solutions.

For media enquiries, please contact:

Janelle Low
Aevice Health Pte Ltd
Email: janellelow@aevice.com

Sarah D’Souza
Jiva.AI
Email: sarah.dsouza@jiva.ai

Aevice Health Secures US FDA Clearance for Remote Respiratory Monitoring Platform Enabled by Smart Wearable Stethoscope

 Singapore, 20 July 2023 – Aevice Health, a leading provider of remote respiratory monitoring solutions for the healthcare continuum and backed by the Cedars-Sinai Accelerator, today announced that its flagship medical device, the AeviceMD, has received clearance from the U.S. Food and Drug Administration (FDA) as a Class II medical device under the 510(k) route. This clearance empowers the company to market and provide their novel remote monitoring platform to health systems across the country, expanding access to a hassle-free and convenient solution for assessing lung health in clinical and home settings.

The AeviceMD is an integral part of the broader AeviceMD Monitoring System, a comprehensive patient management platform targeted towards chronic respiratory disease management. Leveraging cutting-edge proprietary algorithms, the AeviceMD Monitoring System continuously monitors biomarkers of interest acquired by its smart wearable stethoscope and detects early signs of respiratory exacerbation. The robust platform has completed trials in the emergency department for the analysis of abnormal lung sounds like wheezing against the current standard of care — the clinicians’ own stethoscope-based analysis. The results from these trials are currently being collated and will be disclosed in a separate and forthcoming announcement.

Asthma and COPD, the two most common chronic respiratory diseases, account for over 41 million patients in the US, with authorities expecting the actual prevalence to be higher due to underdiagnosis. These diseases contribute significantly to hospital emergency department visits and readmissions, accounting for over $130B, in direct and indirect costs for the country. Lack of access to post-discharge care and follow-ups are key drivers of the hospitalizations and readmissions.

With the AeviceMD, the clinic can now be brought home. The AeviceMD elevates the ubiquitous stethoscope – an essential tool in every clinic – into a smart, digital, and easily accessible device. Caregivers and patients can simply conduct auscultations using the AeviceMD sensor and conveniently share them with their healthcare professional. Through analysis of these recordings, healthcare providers can accurately identify abnormalities and promptly advise patients, enabling proactive management of lung health.

“This FDA clearance represents a remarkable milestone for our company. While diseases like diabetes or heart failure have seen advancements in technology, there remains a notable lack of comprehensive solutions for respiratory conditions. Unfortunately, the patients requiring these solutions the most are often the ones facing challenges in accessing adequate care. With this clearance, we take a significant stride towards becoming the equivalent of continuous glucose monitors for diabetes, but for respiratory health — a patient-centric, affordable, and accessible solution that empowers patients to achieve a healthy recovery from the comfort of their homes,” said Adrian Ang, CEO of Aevice Health.

As a participant in the Cedars-Sinai Accelerator Class 8, Aevice Health has received invaluable support from the program during its developmental journey in the US. Over the course of the three-month program, the company underwent rigorous mentorship, refining its product-market fit for the US market and strategically shaping its product launch strategy. This was made possible with guidance from clinical key opinion leaders, executive management, operations members of the health system, and investors. As part of their plans, the company is working towards a pilot program with the Cedars-Sinai Medical Center. Additionally, Coronet Ventures, the international Cedars-Sinai organization, has participated in Aevice Health’s bridging round with an undisclosed investment.

2023 has been a momentous year for the AeviceMD thus far. This announcement comes at the heels of the company’s recent Singapore Health Sciences Authority (HSA) first-in-market approval for the AeviceMD Monitoring System in March. Earlier in January, the device was awarded the coveted CES® 2023 Best of Innovation Award in the digital health category, an award recognizing the best of breakthrough technologies improving health equity and saving lives.

This FDA-clearance is the first for the product and paves the way for expanded indications that encompass the full range of features offered by the platform. This includes the AeviceMD Monitoring System’s proprietary lung-sound analyzing algorithm which the company plans to clear in near future.

About Aevice Health

Aevice Health is a digital health company dedicated to improving asthma and COPD care through its proprietary, non-invasive remote patient monitoring platform and wearable stethoscope, the AeviceMD. Its cutting-edge technology allows for continuous monitoring and real-time disease deterioration tracking, enabling patients to receive personalized care from the comfort of their homes. With actionable insights and effortless treatment response monitoring, healthcare professionals can make timely adjustments for optimized patient outcomes. Aevice Health is on a mission to improve healthcare accessibility, empower patients, and reduce healthcare costs.

More information about the company can be found at www.aevice.com.

For media enquiries, please contact:

Janelle Low
Aevice Health Pte Ltd
Email: janellelow@aevice.com